Breaking News
Get 40% Off 0
📈 Free Gift Friday: Instantly Copy Legendary Investors' Portfolios Copy for Free
Close

Pangaea Oncology SA (PANGO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.84 +0.07    +3.95%
10:00:18 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Spain
ISIN:  ES0105221008 
  • Volume: 3,349
  • Bid/Ask: 1.80 / 1.84
  • Day's Range: 1.80 - 1.84
Pangaea Oncology 1.84 +0.07 +3.95%

Pangaea Oncology SA Company Profile

 
Get an in-depth profile of Pangaea Oncology SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

57

Equity Type

ORD

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2006 and is based in Barcelona, Spain.

Contact Information

Address Sabino Arana, 5-19
Barcelona, 08028
Spain
Phone 34 93 409 79 81
Fax 34 93 546 01 72

Top Executives

Name Age Since Title
Rafael Lopez-Dieguez Gamoneda - - Independent Director
Jose Antonio Maestre Alcacer - - Director
Camilo Lopez Vaquez - - Director
Carolina Pascual Bernabeu - - Director
Alfonso Francisco Hidalgo Enguix - - Director
Carlos Gustavo Genzor Asin - - Director
Alfonso Pitarch Rodriguez - - Director
Javier Rivela-Rodriguez - - Co-Founder, CEO & Director
Rafael Rosell Costa - - Chief Scientific Officer, President & Member of Scientific Committee
Luis Barcelona Escartin - - Independent Director
Santiago Ramon y Cajal Agueras - - VP, Member of the Scientific Committee and Director
Teresa Macarulla - - Member of the Scientific Advisory Board
Miguel Angel Molina - - Executive Director of Research & Development and Member of Scientific Committee
Ramon Raventos Basagoiti - - Independent Director
Aleix Prat - - Member of the Scientific Advisory Board
Enriqueta Felip - - Member of the Scientific Advisory Board
Josep Taberner - - Member of the Scientific Advisory Board
Miguel Angel Bonachera Sierra - - Independent Director
Maria Gonzalez Cao - - Member of the Scientific Advisory Board
Francesc Bosch - - Member of the Scientific Advisory Board
Francois Quenet - - Member of the Scientific Advisory Board
Javier Cortes - - Member of the Scientific Advisory Board
Antoni Torres - - Member of the Scientific Advisory board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PANGO Comments

Write your thoughts about Pangaea Oncology SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
alex inve
alexinve Jan 25, 2021 10:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
0.46€ Book value/share. TP 0.65€ (in 10 months) if the final profits of the company are not due to its product sales. Otherwise, volatility in 3 months might get us to 1€ per share again and if profits are due to product sales or the partnership with Turning Points (from US) goes well, target price beyond 4€. If Totem study goes well and repotrectinib and osimertinib for advanced lung cancer are effective, Pangaea may be the new Pharma Mar and increase its price towards 10€/share.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email